OCS
NASDAQ HealthcareOculis Holding AG - Ordinary shares
Biotechnology
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
�� 市场数据
| 价格 | $27.46 |
|---|---|
| 成交量 | 366,045 |
| 市值 | 1.59B |
| 贝塔系数 | 0.210 |
| RSI（14日） | 75.0 超买 |
| 200日均线 | $21.68 |
| 50日均线 | $27.31 |
| 52周最高 | $30.68 |
| 52周最低 | $16.00 |
| Forward P/E | -12.73 |
| Price / Book | 6.36 |
🎯 投资策略评分
OCS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (57/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (9/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OCS in your text
粘贴任何文章、记录或帖子 — 工具将提取 OCS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.